antiviral news

Study Results Position Ensitrelvir as Potential First Oral Antiviral for COVID-19 Post-Exposure Prevention

The landscape of viral prophylaxis is shifting from a reliance on systemic immune priming to targeted molecular intervention. Japan has recently pivoted its clinical strategy by approving the preventive use of Xocova, an oral medication designed to halt the viral replication cycle before symptoms manifest, marking a significant departure from standard post-diagnostic treatment. Key Clinical […] You can read the full story here: New Japanese Oral Drug Effectively Prevents Covid .

The results mark the first late-stage success for an oral antiviral used to prevent COVID-19 after exposure.

Paxlovid’s role in treating COVID-19 is not ending — it is evolving, according to the results of two national trials published in The New England Journal of Medicine.Although the trials — one conducted in the United Kingdom (PANORAMIC) and the other in Canada (CanTreatCOVID) — determined that Paxlovid (nirmatrelvir-ritonavir, Pfizer) does not reduce the incidence of hospitalization or death among vaccinated high-risk patients with SARS-CoV-2 compared with usual care, the combination medication sped up recovery in a meaningful way, experts noted.Nirmatrelvir-ritonavir is an antiviral regimen

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, were published in the New England Journal of Medicine. A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compare

Study found nirmatrelvir–ritonavir did not reduce severe outcomes in vaccinated COVID-19 patients, though symptom recovery improved.